¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå : Á¦Ç° À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2031³â)
Biosimilars Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
»óǰÄÚµå : 1470724
¸®¼­Ä¡»ç : Persistence Market Research
¹ßÇàÀÏ : 2024³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 250 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,995 £Ü 6,922,000
Unprintable PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ º¹»ç, ÀμⰡ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 7,295 £Ü 10,109,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste¿Í ÀμⰡ °¡´ÉÇÕ´Ï´Ù.
US $ 8,495 £Ü 11,772,000
PDF & Excel (Corporate User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste¿Í ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå Á¶»ç º¸°í¼­´Â ½ÃÀå ¿ªÇÐ, ¼ºÀå¿äÀÎ, °úÁ¦, ½Å±Ô µ¿Çâ µîÀ» Æø³Ð°Ô ºÐ¼®Çϰí ÀÖ½À´Ï´Ù. 2024-2031³â ½ÃÀåÀÇ ±ËÀû¿¡ °üÇÑ µ¥ÀÌÅÍ¿Í Åë°è¸¦ ´Ù·ç°í, ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀÇ ÇöȲ°ú Àü¸Á¿¡ °üÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀº 2024³â 315¾ï ´Þ·¯¿¡¼­ CAGR 14.1%·Î ¼ºÀåÇϸç, 2031³â¿¡´Â 1,001¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÁÖ¿ä ÀλçÀÌÆ®

¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå - ¸®Æ÷Æ® ¹üÀ§ :

¹ÙÀÌ¿À½Ã¹Ð·¯¶õ ±âÁ¸ »ý¹°ÇÐÀû Á¦Á¦¿Í À¯»ç¼ºÀÌ ³ôÀº »ý¹°ÇÐÀû Á¦Á¦¸¦ ¸»Çϸç, ·¹ÆÛ·±½º Á¦Á¦ ¶Ç´Â ¿À¸®Áö³×ÀÌÅÍ Á¦Á¦¶ó°íµµ ÇÕ´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå¿¡´Â ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, ´ç´¢º´, °¨¿°¼º Áúȯ µî ´Ù¾çÇÑ Ä¡·á Ä«Å×°í¸®°¡ Æ÷ÇԵ˴ϴÙ. ÀÌ º¸°í¼­´Â ºñ¿ë È¿À²¼º, »ý¹°ÇÐÀû Á¦Á¦ÀÇ Æ¯Çã ¸¸·á, Àú·ÅÇÑ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¹ÙÀÌ¿À½Ã¹Ð·¯ ¼ö¿ä¸¦ Áö¿øÇÏ´Â ÁÖ¿ä ¿äÀο¡ ´ëÇØ ¼³¸íÇÕ´Ï´Ù. ¶ÇÇÑ ¹ÙÀÌ¿À±â¼ú, Á¦Á¶ °øÁ¤ ¹× ±ÔÁ¦ °æ·ÎÀÇ ¹ßÀüÀº ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰ ½ÃÀå °³¹ß, ½ÂÀÎ ¹× »ó¿ëÈ­¸¦ ÃËÁøÇÏ¿© ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¼ºÀåÀÇ ÃËÁø¿äÀÎ:

½ÃÀå ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ù°, °í°¡ÀÇ »ý¹°ÇÐÀû Á¦Á¦¸¦ ´ëüÇÒ ¼ö ÀÖ´Â ºñ¿ë È¿À²ÀûÀÎ ´ë¾È¿¡ ´ëÇÑ ¼ö¿ä°¡ ¹ÙÀÌ¿À½Ã¹Ð·¯¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ¿© ȯÀÚ, ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ ¹× ÁöºÒÀÚ¿¡°Ô »ó´çÇÑ ºñ¿ë Àý°¨ È¿°ú¸¦ °¡Á®´ÙÁÝ´Ï´Ù. ¶ÇÇÑ ºí·Ï¹ö½ºÅÍ »ý¹°ÇÐÀû Á¦Á¦ÀÇ Æ¯Çã ¸¸·á´Â ¹ÙÀÌ¿À½Ã¹Ð·¯ Á¦Á¶¾÷ü°¡ ½ÃÀå¿¡ ÁøÀÔÇÏ¿© Àú·ÅÇÑ ´ë¾ÈÀ» Á¦°øÇÔÀ¸·Î½á ½ÃÀå °æÀï°ú Çʼö Ä¡·áÁ¦¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ÃËÁøÇÒ ¼ö ÀÖ´Â ±âȸ¸¦ âÃâÇÕ´Ï´Ù. ¶ÇÇÑ ÀÇ·áÁø, ȯÀÚ ¹× ±ÔÁ¦ ´ç±¹ÀÌ ¹ÙÀÌ¿À½Ã¹Ð·¯¸¦ ´õ ¸¹ÀÌ ¼ö¿ëÇÏ°Ô µÇ¸é ¾ÈÀü¼º, À¯È¿¼º ¹× ÂüÁ¶ »ý¹°ÇÐÀû Á¦Á¦¿ÍÀÇ È£È¯¼º¿¡ ´ëÇÑ ¿ì·Á¸¦ ÇØ¼ÒÇÏ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ :

Àü¸ÁÀº ¹àÁö¸¸, ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀº ÀÏÁ¤ÇÑ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ±ÔÁ¦ÀÇ º¹À⼺, ÁöÀûÀç»ê±Ç ¹®Á¦, ½ÃÀå ÁøÀÔ À庮Àº ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰÀÇ °³¹ß, ½ÂÀÎ ¹× »ó¾÷È­¿¡ ¿µÇâÀ» ¹ÌÃÄ ½ÃÀå ¿ªÇÐ ¹× °æÀï ±¸µµ¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼¼Æ÷ÁÖ °³¹ß, °øÁ¤ ÃÖÀûÈ­, ǰÁú °ü¸®¿Í °°Àº Á¦Á¶»óÀÇ º¹À⼺Àº ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰ Á¦Á¶¾÷ü°¡ Á¦Ç°ÀÇ ºñ±³ °¡´É¼º ¹× ÂüÁ¶ »ý¹°ÇÐÀû Á¦Á¦¿ÍÀÇ Àϰü¼ºÀ» º¸ÀåÇÏ´Â µ¥ ¾î·Á¿òÀ» °ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ °¡°Ý ¾Ð·Â, »óȯ Á¤Ã¥, ½ÃÀå µ¶Á¡±Ç µî ½ÃÀå ¿ªÇÐÀº ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå ÁøÀÔ°ú ½ÃÀå ħÅõ¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå È®´ë¿Í ¼öÀͼº¿¡ µµÀüÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ±âȸ :

¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀº ¼ºÀå°ú Çõ½ÅÀ» À§ÇÑ Å« ±âȸ°¡ ÀÖ½À´Ï´Ù. Á¦Á¶¾÷üµéÀº Èñ±ÍÁúȯ, Èñ±ÍÁúȯ Ä¡·áÁ¦, Ư¼ö »ý¹°ÇÐÀû Á¦Á¦ µî Æ´»õ Ä¡·á ºÐ¾ß¸¦ À§ÇÑ ¹ÙÀÌ¿À½Ã¹Ð·¯ Á¦Ç° °³¹ß¿¡ ÁýÁßÇÏ¿© ¹ÌÃæÁ· ÀÇ·á ¼ö¿ä¿Í ½ÃÀå °ÝÂ÷¸¦ ÇØ¼ÒÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹ÙÀÌ¿À Á¦¾à»ç, À§Å¹°³¹ß ¹× Á¦Á¶¼öʱâ°ü(CDMO), ¿¬±¸±â°ü°úÀÇ Àü·«Àû ÆÄÆ®³Ê½Ê, Á¦ÈÞ, ¶óÀ̼±½º °è¾àÀ» ÅëÇØ ±â¼ú ÀÌÀü, ÀÚ¿ø °øÀ¯, Áö½Ä ±³·ù¸¦ ÃËÁøÇÏ¿© ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰÀÇ °³¹ß ¹× »ó¿ëÈ­¸¦ ÃËÁøÇÒ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« µî ½ÅÈï ½ÃÀåÀ¸·ÎÀÇ ÁøÃâÀº ½ÃÀå È®´ë ¹× Æ÷Æ®Æú¸®¿À ´Ù°¢È­ ±âȸ¸¦ Á¦°øÇÏ¿© Àú·ÅÇÑ °¡°ÝÀÇ »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ȯÀÚ ¼ö Áõ°¡¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

º» ¸®Æ÷Æ®¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

Á¦3Àå ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ÁÖ¿ä ¼º°ø¿äÀÎ

Á¦5Àå ¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀÇ ¼ö¿ä ºÐ¼®(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)

Á¦6Àå ¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå - °¡°Ý ºÐ¼®

Á¦7Àå ¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀÇ ¼ö¿ä ºÐ¼®(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)

Á¦8Àå ½ÃÀå ¹è°æ

Á¦9Àå ¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå ºÐ¼®(2019-2023³â)°ú ¿¹Ãø(2024-2031³â) : Á¦Ç° À¯Çüº°

Á¦10Àå ¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå ºÐ¼®(2019-2023³â)°ú ¿¹Ãø(2024-2031³â) : ¿ëµµº°

Á¦11Àå ¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå ºÐ¼®(2019-2023³â)°ú ¿¹Ãø(2024-2031³â) : À¯Åë ä³Îº°

Á¦12Àå ¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå ºÐ¼®(2019-2023³â)°ú ¿¹Ãø(2024-2031³â) : Áö¿ªº°

Á¦13Àå ºÏ¹ÌÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå ºÐ¼®(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)

Á¦14Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå ºÐ¼®(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)

Á¦15Àå À¯·´ÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå ºÐ¼®(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)

Á¦16Àå ³²¾Æ½Ã¾Æ¡¤ÅÂÆò¾çÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå ºÐ¼®(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)

Á¦17Àå µ¿¾Æ½Ã¾ÆÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå ºÐ¼®(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)

Á¦18Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå ºÐ¼®(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)

Á¦19Àå ½ÅÈï ±¹°¡ÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå ºÐ¼®

Á¦20Àå ½ÃÀå ±¸Á¶ ºÐ¼®

Á¦21Àå °æÀï ºÐ¼®

Á¦22Àå ÀüÁ¦¿Í µÎÀÚ¾î

Á¦23Àå Á¶»ç ¹æ¹ý

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Biosimilars Market report by Persistence Market Research provides an extensive analysis of market dynamics, growth factors, challenges, and emerging trends. It encompasses data and statistics on the market's trajectory from 2024 to 2031, offering insights into the current state and future outlook of the Biosimilars Market.

The global biosimilars market is anticipated to grow at a compound annual growth rate (CAGR) of 14.1% from USD 31.5 billion in 2024 to USD 100.1 billion by 2031.

Key Insights:

Biosimilars Market - Report Scope:

Biosimilars are biologic medical products that are highly similar to existing biologic products, also known as reference or originator products. The biosimilars market encompasses a wide range of therapeutic categories, including oncology, autoimmune diseases, diabetes, and infectious diseases, among others. The report outlines key drivers behind the demand for biosimilars, including cost-effectiveness, patent expiries of biologic drugs, and increasing demand for affordable treatment options. Moreover, advancements in biotechnology, manufacturing processes, and regulatory pathways drive market growth by facilitating the development, approval, and commercialization of biosimilar products.

Market Growth Drivers:

The market's growth is propelled by several factors. Firstly, the need for cost-effective alternatives to expensive biologic drugs drives demand for biosimilars, offering significant cost savings for patients, healthcare providers, and payers. Additionally, patent expiries of blockbuster biologic drugs create opportunities for biosimilar manufacturers to enter the market and offer affordable alternatives, driving market competition and access to essential therapies. Moreover, increasing acceptance of biosimilars by healthcare professionals, patients, and regulatory authorities fosters market growth by addressing concerns related to safety, efficacy, and interchangeability with reference biologics.

Market Restraints:

Despite the positive outlook, the Biosimilars Market faces certain challenges. Regulatory complexities, intellectual property issues, and market access barriers may impact the development, approval, and commercialization of biosimilar products, influencing market dynamics and competitive landscape. Moreover, manufacturing complexities, including cell line development, process optimization, and quality control, pose challenges to biosimilar manufacturers in ensuring product comparability and consistency with reference biologics. Additionally, market dynamics such as pricing pressures, reimbursement policies, and market exclusivity rights may impact biosimilar uptake and market penetration, posing challenges to market expansion and profitability.

Market Opportunities:

The Biosimilars Market offers significant opportunities for growth and innovation. Manufacturers can focus on developing biosimilar products for niche therapeutic areas, including rare diseases, orphan drugs, and specialty biologics, addressing unmet medical needs and market gaps. Moreover, strategic partnerships, collaborations, and licensing agreements with biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), and research institutions facilitate technology transfer, resource sharing, and knowledge exchange, driving biosimilar development and commercialization. Furthermore, expansion into emerging markets, including Asia Pacific, Latin America, and Middle East & Africa, offers opportunities for market expansion and portfolio diversification, tapping into growing demand for affordable biologic therapies and expanding patient populations.

Key Questions Addressed in the Report:

Competitive Landscape and Business Strategies:

Key players in the Biosimilars Market include Amgen Inc., Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., and Biocon Limited. These companies focus on product development, regulatory strategies, and market access initiatives to differentiate themselves in the market and gain a competitive edge. For instance, Amgen Inc. is known for its biosimilar portfolio, including products such as Neupogen (filgrastim) biosimilar, while Pfizer Inc. specializes in biosimilar versions of blockbuster biologic drugs such as Humira (adalimumab). Market players also invest in research and development, manufacturing capabilities, and global expansion to enhance their biosimilar pipelines, address market needs, and capture market share in key therapeutic categories and geographic regions.

Key Companies Profiled:

Biosimilars Market Segmentation:

By Product Type:

By Application:

By Distribution Channel:

By Region:

Table of Contents

1. Executive Summary

2. Market Overview

3. Key Market Trends

4. Key Success Factors

5. Global Biosimilars Market Demand Analysis 2019-2023 and Forecast, 2024-2031

6. Global Biosimilars Market - Pricing Analysis

7. Global Biosimilars Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2031

8. Market Background

9. Global Biosimilars Market Analysis 2019-2023 and Forecast 2024-2031, by Product Type

10. Global Biosimilars Market Analysis 2019-2023 and Forecast 2024-2031, By Application

11. Global Biosimilars Market Analysis 2019-2023 and Forecast 2024-2031, By Distribution Channel

12. Global Biosimilars Market Analysis 2019-2023 and Forecast 2024-2031, by Region

13. North America Biosimilars Market Analysis 2019-2023 and Forecast 2024-2031

14. Latin America Biosimilars Market Analysis 2019-2023 and Forecast 2024-2031

15. Europe Biosimilars Market Analysis 2019-2023 and Forecast 2024-2031

16. South Asia and Pacific Biosimilars Market Analysis 2019-2023 and Forecast 2024-2031

17. East Asia Biosimilars Market Analysis 2019-2023 and Forecast 2024-2031

18. Middle East and Africa Biosimilars Market Analysis 2019-2023 and Forecast 2024-2031

19. Emerging Countries Biosimilars Market Analysis

20. Market Structure Analysis

21. Competition Analysis

22. Assumptions and Acronyms Used

23. Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â